November 12, 2009 08:00 ET

OPTIMIZERx Moves to the OTC Bulletin Board

ROCHESTER, MI--(Marketwire - November 12, 2009) - OPTIMIZERx Corporation (OTCBB: OPRX) announced today that it has moved from the OTC Pink Sheets listing and is now on the OTC Bulletin Board.

"Being cleared for the OTC Bulletin Board is a big step for OPTIMIZERx and its investors," said David Lester, CEO of OPTIMIZERx. "It will provide greater outside investment opportunity into OPTIMIZERx as we continue to develop and introduce new solutions to the marketplace."

OPTIMIZERx recently announced the introduction of SampleMD, a new solution for the distribution and administration of drug sampling and prescribed therapy persistency program at the Pharmaceutical Sampling conference in Philadelphia. "The conference validated that the industry is ready for a new approach at administrating and distributing branded samples," said David Harrell, Chairman of OPTIMIZERx and creator of SampleMD. "With fewer physicians no longer seeing drug reps, along with increasing compliance factors associated with distributing physical drug samples, pharmaceutical manufacturers are looking for new channels to the physicians and health care providers." To learn more about SampleMD, visit

About OPTIMIZERx Corporation

OPTIMIZERx provides unique platforms to help patients better afford and comply to their medicines and healthcare products, while offering pharmaceutical and healthcare companies effective ways to expand patient awareness, access and adherence to their brands. The Company's patient support website,, and its permanent subscriber base, continue to grow each month and is quickly becoming the preferred way to access branded prescription savings and support programs. Additionally, OPTIMIZERx has developed OFFERx™ and ADHERxE™ to allow a more streamlined, effective way to create, promote and manage new trial or co-pay programs on behalf of brand-name pharmaceuticals and health care products.


This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended and such section 21E of the Securities Act of 1934, amended. These forward-looking statements should not be used to make an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Contact Information

  • Contact:
    David Lester